Garber J E, Goldstein A M, Kantor A F, Dreyfus M G, Fraumeni J F, Li F P
Epidemiology and Biostatistics Program, National Cancer Institute, Bethesda, Maryland 20892.
Cancer Res. 1991 Nov 15;51(22):6094-7.
The Li-Fraumeni cancer family syndrome is manifested by susceptibility to breast cancer, sarcomas, and other neoplasms in children and young adults. The present study utilized clinical follow-up data on 545 members of 24 Li-Fraumeni kindreds living and cancer-free at family ascertainment. Two hypotheses were tested based on a model of autosomal dominant genetic predisposition: (a) that syndrome cancers would continue to occur excessively during follow-up compared to the general population, and (b) that the tumors would occur primarily among those family members likely to carry the gene. Population cancer rates were compared with cancer rates in follow-up of the cohort from ascertainment to 1988. Risk of carrying the gene for the syndrome at the time of ascertainment was calculated for each family member under two models with somewhat different definitions of affection with the syndrome. Cancer occurrence after ascertainment was then analyzed according to the risks. Cancer did continue to occur excessively among the entire cohort during follow-up [relative risk (RR 2.1)]. The excess was greatest below age 20 (RR 21.1), declined with increasing age, and was most pronounced for neoplasms featured in the syndrome (RR 18.2). Among persons less than age 45, at least 87% of cancers occurred in those at higher risk of carrying the gene under both genetic models (RR 22.9 and 21.3). The clinical data, therefore, reliably identify individuals likely to carry a dominantly inherited gene conferring susceptibility to a specific constellation of neoplasms. Recent identification of a germ line mutation in the tumor suppressor gene p53 in persons with the syndrome may, if confirmed, have implications for ultimately defining the component tumors of the syndrome and for the causes and prevention of those tumors arising outside these families.
李-弗劳梅尼癌症家族综合征表现为儿童和青年易患乳腺癌、肉瘤及其他肿瘤。本研究利用了24个李-弗劳梅尼家族中545名成员的临床随访数据,这些成员在家族确诊时健在且无癌症。基于常染色体显性遗传易感性模型检验了两个假设:(a)与一般人群相比,综合征相关癌症在随访期间仍会过度发生;(b)肿瘤主要发生在可能携带该基因的家族成员中。将人群癌症发病率与该队列从确诊到1988年随访期间的癌症发病率进行了比较。根据两种对综合征患病情况定义略有不同的模型,计算了每个家族成员在确诊时携带该综合征基因的风险。然后根据风险分析确诊后的癌症发生情况。在随访期间,整个队列中的癌症确实继续过度发生[相对风险(RR) 2.1]。这种过度在20岁以下最为明显(RR 21.1),随着年龄增长而下降,在综合征特征性肿瘤中最为显著(RR 18.2)。在45岁以下的人群中,在两种遗传模型下,至少87%的癌症发生在携带基因风险较高的人群中(RR 22.9和21.3)。因此,临床数据能够可靠地识别可能携带显性遗传基因、易患特定肿瘤组合的个体。最近在患有该综合征的人群中发现肿瘤抑制基因p53的种系突变,若得到证实,可能最终对确定该综合征的组成肿瘤以及这些家族以外发生的那些肿瘤的病因和预防具有重要意义。